104 related articles for article (PubMed ID: 38730156)
1. Clinical status of established MRONJ in oncology patients continuing bone-modifying agents.
Miles E; Arya R; Sproat C; Patel V
Br Dent J; 2024 May; 236(9):683-687. PubMed ID: 38730156
[TBL] [Abstract][Full Text] [Related]
2. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
Hasegawa T; Hayashida S; Kondo E; Takeda Y; Miyamoto H; Kawaoka Y; Ueda N; Iwata E; Nakahara H; Kobayashi M; Soutome S; Yamada SI; Tojyo I; Kojima Y; Umeda M; Fujita S; Kurita H; Shibuya Y; Kirita T; Komori T;
Osteoporos Int; 2019 Jan; 30(1):231-239. PubMed ID: 30406309
[TBL] [Abstract][Full Text] [Related]
3. MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series.
Mauceri R; Coppini M; Attanasio M; Bedogni A; Bettini G; Fusco V; Giudice A; Graziani F; Marcianò A; Nisi M; Isola G; Leonardi RM; Oteri G; Toro C; Campisi G
BMC Oral Health; 2023 Feb; 23(1):71. PubMed ID: 36739399
[TBL] [Abstract][Full Text] [Related]
4. Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer.
Ueda N; Aoki K; Shimotsuji H; Nakashima C; Kawakami M; Imai Y; Kirita T
J Bone Miner Metab; 2021 Jul; 39(4):623-630. PubMed ID: 33420576
[TBL] [Abstract][Full Text] [Related]
5. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
[TBL] [Abstract][Full Text] [Related]
6. Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals.
Drudge-Coates L; Van den Wyngaert T; Schiødt M; van Muilekom HAM; Demonty G; Otto S
Support Care Cancer; 2020 Sep; 28(9):4019-4029. PubMed ID: 32307659
[TBL] [Abstract][Full Text] [Related]
7. Pain characteristics in medication-related osteonecrosis of the jaws.
Haviv Y; Geller Z; Mazor S; Sharav Y; Keshet N; Zadik Y
Support Care Cancer; 2021 Feb; 29(2):1073-1080. PubMed ID: 32601851
[TBL] [Abstract][Full Text] [Related]
8. Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?
Ueda N; Nakashima C; Aoki K; Shimotsuji H; Nakaue K; Yoshioka H; Kurokawa S; Imai Y; Kirita T
Clin Oral Investig; 2021 May; 25(5):3087-3093. PubMed ID: 33057886
[TBL] [Abstract][Full Text] [Related]
9. The trend of dental check-up and prevalence of dental complications following the use of bone modifying agents in patients with metastatic breast and prostate cancer: analysis of data from the Korean National Health Insurance Service.
Lim AR; Park W; Moon SJ; Kim MS; Lee S
BMC Health Serv Res; 2024 Apr; 24(1):412. PubMed ID: 38566103
[TBL] [Abstract][Full Text] [Related]
10. Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients.
Soutome S; Otsuru M; Hayashida S; Murata M; Yanamoto S; Sawada S; Kojima Y; Funahara M; Iwai H; Umeda M; Saito T
Sci Rep; 2021 Aug; 11(1):17226. PubMed ID: 34446755
[TBL] [Abstract][Full Text] [Related]
11. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
12. Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.
Galis B; Zajko J; Hirjak D; Vanko L; Kupcova I; Jurkemik J; Gengelova P; Mikuskova K; Halmova K; Riznic M; Czako L
Bratisl Lek Listy; 2017; 118(12):724-731. PubMed ID: 29322803
[TBL] [Abstract][Full Text] [Related]
13. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?
Hasegawa T; Kawakita A; Ueda N; Funahara R; Tachibana A; Kobayashi M; Kondou E; Takeda D; Kojima Y; Sato S; Yanamoto S; Komatsubara H; Umeda M; Kirita T; Kurita H; Shibuya Y; Komori T;
Osteoporos Int; 2017 Aug; 28(8):2465-2473. PubMed ID: 28451732
[TBL] [Abstract][Full Text] [Related]
14. A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy.
Fusco V; Cabras M; Erovigni F; Dell'Acqua A; Arduino PG; Pentenero M; Appendino P; Basano L; Ferrera FD; Fasciolo A; Caka M; Migliario M
Med Oral Patol Oral Cir Bucal; 2021 Jul; 26(4):e466-e473. PubMed ID: 33340073
[TBL] [Abstract][Full Text] [Related]
15. Medication-related osteonecrosis of the jaw: knowledge and perceptions of medical professionals on the usage of bone modifying agents and dental referrals.
Acharya S; Patil V; Ravindranath V; Kudva A; Nikhil K
J Med Life; 2022 Mar; 15(3):368-373. PubMed ID: 35449990
[TBL] [Abstract][Full Text] [Related]
16. Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer.
Sim IeW; Sanders KM; Borromeo GL; Seymour JF; Ebeling PR
J Clin Endocrinol Metab; 2015 Oct; 100(10):3887-93. PubMed ID: 26241323
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
[TBL] [Abstract][Full Text] [Related]
18. Medication-Related Osteonecrosis of the Jaw: A Cross-Sectional Study on the Prevalence of Cutaneous Manifestations and the Primary Care Physician's Role in its Early Diagnosis.
Whitefield S; Ilan MB; Lazarovici TS; Friedlander-Barenboim S; Kassem R; Yarom N
Am J Med; 2024 Mar; 137(3):266-272. PubMed ID: 38042241
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and treatment of medication-related osteonecrosis of the jaws from an oncologist's perspectives].
Yuan P
Zhonghua Kou Qiang Yi Xue Za Zhi; 2021 May; 56(5):415-420. PubMed ID: 33904274
[TBL] [Abstract][Full Text] [Related]
20. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
